The 66th American Society of Hematology (ASH) Annual Meeting will be held from December 7-10, 2024, in San Diego, USA. As the world’s largest and most comprehensive international academic conference in hematology, ASH attracts thousands of experts and scholars from around the globe each year, who come to share cutting-edge developments and breakthrough clinical data. At this year’s conference, Prof. Xiaohui Zhang’s team from the Department of Hematology, Peking University People’s Hospital, and the Institute of Hematology, Peking University, will showcase an impressive total of 11 studies, including three selected for oral presentations, underscoring China’s outstanding achievements in hematology research. This preview highlights these three oral presentations, inviting readers to follow the presentation schedules and learn more about the fascinating details and stories behind these impactful studies.

Oral Presentation 1

Part.01

• Abstract Number: 300
• Title: Effects of Low-Molecular-Weight Heparin on Pregnancy Outcomes in Protein S Deficiency: A Prospective, Randomized Controlled Phase II Clinical Trial
• First Author: Mengtong Zang
• Presentation Time: December 7, 2024, 5:15 PM (local time)
• Location: Room 29, San Diego Convention Center

Oral Presentation 2

Part.02

• Abstract Number: 425
• Title: β2-Adrenergic Receptor Agonist Terbutaline Regulates Macrophage Polarization Via HMGB1 in Immune Thrombocytopenia
• First Author: Qiuyu Guo
• Presentation Time: December 8, 2024, 10:30 AM (local time)
• Location: Room 28 A-D, San Diego Convention Center

Oral Presentation 3

Part.03

• Abstract Number: 712
• Title: Biomarker MSC-C5b-9-guided All-Trans Retinoic Acid Treatment for Resistant/Recurrent ITP: A Multicenter, Randomized, Open-Label, Phase 3 Clinical Trial
• First Author: Menglin Li
• Presentation Time: December 9, 2024, 11:15 AM (local time)
• Location: Room 29, San Diego Convention Center

Prof. Xiaohui Zhang

• Vice Director, Department of Hematology, Peking University People’s Hospital & Peking University Institute of Hematology
• Deputy Director and Office Director, National Clinical Research Center for Hematologic Diseases
• Deputy Chair, Hematology Branch of the Chinese Medical Association and Chair, Hematopoietic Stem Cell Application Group
• Deputy Chair, Hematology Immunology Committee of the Chinese Society for Immunology
• Chairperson and President, Hematology Working Committee, Beijing Cancer Prevention Society
• Leads major national projects, including the National Key R&D Program, the National Natural Science Foundation, and major capital health research projects
• Authored or led over 30 national expert guidelines and consensus papers, edited five hematology monographs, and holds 14 national invention patents
• Published over 130 SCI papers in Nat. Immunol., J Hematol Oncol, Lancet Hematol, Blood, Nat. Commun., Am J Hematol, Leukemia, etc.
• Honored with the “Outstanding Contribution Award of National Famous Physicians”
• As the lead researcher, received the First Prize in the Huaxia Medical Science and Technology Award and the Second Prize in the Chinese Medical Science and Technology Award
• As a contributing researcher, received two National Science and Technology Progress Awards (Second Prize)

Prof. Xiaohui Zhang’s team’s participation in ASH 2024 promises to bring international attention to these cutting-edge studies in hematology. Don’t miss this opportunity to witness China’s expertise in hematology research and to explore the impactful studies presented at the conference.